{
    "nctId": "NCT06532812",
    "briefTitle": "TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer",
    "officialTitle": "Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 85,
    "primaryOutcomeMeasure": "Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 16 years to 90 years\n* Histologically diagnosed as primary/relapsed/metastasized brain glioma\n* Expected life span more than 3 months\n* Karnofsky\u226560% or ECOG score 0-2\n* Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n* Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated\n* At least 1 evaluable tumor lesion\n* Hematology and Chemistry\uff08within 7 days prior to enrollment\uff09:\n* Absolute count of white blood cells\u22652.5\u00d710\\^9/L\n* Absolute count of neutropils\u22651.5\u00d710\\^9/L\n* Absolute count of lymphocytes \u22650.7\u00d7109/L\n* Platelet count\u2265100\u00d710\\^9\n* hemoglobin\u226590 g/L\n* Activated partial thromboplastin time (APTT) \u22641.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* International normalized ratio (INR) \u22641.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* Serum creatinine \u22641.5mg/dL(or \u2264132.6\u03bcmol/L), or clearance rate\u226550mL/min\n* Serum ALT/AST \u22643\u00d7ULN(subjects with liver metastasis \u22643\u00d7ULN)\n* Totol bilirubin\u22641.5\u00d7ULN\n* No absolute or relative contraindications to operation or biopsy\n* Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion\n* Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs\n* Be able to understand and sign the informed consent document;\n* Be able to stick to follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment\n* Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%\n* Significant cardiovascular anomalies according to any of the following definitions:\n* New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant\n* Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc.\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive.\n* Severe physical or mental diseases;\n* Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection).\n* Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy.\n* History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy.\n* Having received immunotherapy and developed an irAE level greater than Level 3.\n* Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded).\n* Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.\n* Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.",
    "sex": "ALL",
    "minimumAge": "16 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}